GSK prepares to cash in on bird flu fears
Wednesday 19 October 2005
The company is hoping to benefit from the contingency plans of worried governments and corporations, as Roche, its Swiss rival, struggles to keep up with demand for Tamiflu, its flu treatment and the most widely regarded means of treating any outbreak of avian flu.
The Swiss company is likely to say today that it has witnessed a significant upswing in orders for Tamiflu, as it reports its latest quarterly results. It received US approval yesterday for a new Tamiflu manufacturing plant but was having to bat away growing calls for the company to give up patents and allow other pharmaceuticals companies to make the pills.
GSK's Relenza acts in a similar way to help fight the flu virus but is regarded as less reliable because it is inhaled, not swallowed. That might mean people with breathing difficulties do not get the correct dose.
Many governments are likely to resist calls to stockpile GSK's drug because of this drawback and because neither drug is wholly effective, only lessening the symptoms if taken early enough. The UK Government is buying 14.6 million doses of Tamiflu, enough to treat a quarter of the population.
GSK said it was enjoying significant interest in Relenza and was talking to several governments about contributing to bird flu stockpiles. One City analyst said the company might see an additional $1.4bn (£800m) in annual sales of the drug when the new capacity comes on-stream.
The company made 11 million doses of Relenza last year and has invested in new equipment at several manufacturing sites, including at Montrose in Scotland, that will boost capacity to 31 million doses in 2007, with more to follow.
Michael Leacock, a drug sector analyst at Nomura, told clients: "A major opportunity lies in the US, where the joint National Vaccination Advisory Committee and Advisory Committee for Immunization Practices meeting recommended that 133 million treatments of flu drugs be stockpiled in preparation for a possible pandemic. We understand Roche can deliver only 10 million courses of its Tamiflu in 2005 and 12 million in 2006 to the US, despite its new US plant. Relenza is seen as an important back-up product in pandemic flu planning."
Shares in Roche were among the best performers on the Swiss stock exchange yesterday because of investor excitement over Tamiflu, but there are increasing calls for it to give up its monopoly on the product.
Cipla, India's second-largest drug maker, will put in a provocative request today for a licence to make Tamiflu. Several US politicians have demanded Roche allow US companies to set up manufacturing plants.
South Korea ferry: Vice principal rescued from sinking ship found hanged
Missing Malaysia Airlines Flight MH370: Wreckage could be found within a week as search reaches 'very critical juncture', says minister
Royal Tour 2014: Is the Duchess of Cambridge the only person ever to climb into a fighter jet wearing a dress and high heels?
Kim Jong-un, crowds and contraband: Inside North Korea with the Pyongyang marathon winner
Cover up! Mother told to show less cleavage during Disneyland family trip: 'Are we supposed to wear turtlenecks our whole lives?'
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
US Navy christens huge $3 billion destroyer ship USS Zumwalt that appears as a fishing boat on enemy radar
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
Nigel Farage fatigue? Half of voters ‘immune’ to Ukip’s appeal
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
'Sinful': Video of British Muslims dancing to Pharrell Williams's hit Happy comes under attack
- 1 Pet cat puts three family members in hospital after launching frenzied attack
- 2 Dylan Tombides: West Ham confirm 20-year-old striker has died after battle with cancer
- 3 24 people applied for the 'world's toughest job', here are their interviews
- 4 Angus Steakhouse: How does tourist staple continue to thrive in today's gourmet market?
- 5 Cover up! Mother told to show less cleavage during Disneyland family trip: 'Are we supposed to wear turtlenecks our whole lives?'
iJobs Money & Business
£150.00 per week: QA Apprenticeships: This company has been providing on site ...
£221.25 per week: QA Apprenticeships: This company is a well established Inter...
£40000 - £50000 per annum: Harrington Starr: Client Relationship Manager - SQL...
£35000 - £50000 per annum: Pro-Recruitment Group: Take your chance to join the...